Pfizer Gets FDA Approval for Bleeding Disorder Treatment
(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t Track‘Seriously Underwater’ Home Mortgages Tick Up Across th
Eli Lilly stock broke out, but then slumped. The FDA is soon to hold a meeting to discuss its Alzheimer's drug. Is LLY stock a buy or a sell?
Risk and reward are the yin and yang of stock trading, the two essential yet opposing forces in every market success. And there are no stocks that better embody both sides – the risk factors and the reward potentials—than penny stocks. Traditionally, these are shares sold for just pennies each; nowadays, they’re the stocks priced under $5 per share. At that low entry cost, even a small gain in absolute value will quickly turn into a high-percentage return—and gains of 400% or higher are not unhe
Pfizer stock ran up to its 50-day line after the company reported better-than-expected sales and profit. Is PFE stock a buy?
Curaleaf CEO Matt Darin said it was "a historic moment" for the cannabis industry following reports that the DEA is seeking to reschedule marijuana. Here are some of the implications for the weed industry.
The company will collaborate with a biotech founded by Flagship Pioneering, the venture capital firm that created Moderna.
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy. The boy was enrolled in Phase 2 DAYLIGHT study studying the treatment in boys at least two years old and under four years old. The patient received the investigational gene therapy, fordadistrogene movaparvovec (PF-06939926), in early 2023. Citing Pfizer, Reuters
TEV-‘749 has met primary endpoint in Phase III trial, showing significant symptom reduction in schizophrenia patients.
The collaboration will focus on evaluating Phanes' antibody PT217 in combination with Roche's atezolizumab.
The two children with rare genetic otoferlin hearing loss enrolled in the Phase I/II trial for Regeneron’s gene therapy observed improvements in hearing.